HSD17B6: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: HSD17B6

NCBI ID: G8630

HSD17B6

HSD17B6: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a major public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant disability and reduced quality of life. The neurotransmitter systems, particularly opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are commonly used to treat chronic pain. However, the overuse of these drugs can lead to various adverse effects. Therefore, it is essential to identify new targets for pain treatment that minimize potential adverse effects. One potential target for pain treatment is the hormone system, specifically the 17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6) gene.

HSD17B6 gene and its function

The HSD17B6 gene is located on chromosome 10q24 and encodes for a protein known as 17-beta-hydroxysteroid dehydrogenase type 6. This protein plays a crucial role in the synthesis and degradation of 17-beta-hydroxysteroids, which are involved in various physiological processes, including pain signaling.

17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6) is a enzyme that converts 17-beta-hydroxysteroids to 17-beta-hydroxysteroid esters. This enzyme is responsible for the synthesis of many natural compounds, including important signaling molecules, such as cortisol, progesterone, and androstenedione. HSD17B6 is also involved in the degradation of various metabolites, including androstenedione, which is a potent endocannabinoid.

HSD17B6 gene and pain

The HSD17B6 gene has been implicated in pain signaling. Several studies have shown that HSD17B6 is involved in the synthesis and degradation of pro-inflammatory compounds, such as androstenedione, which can contribute to pain perception. Additionally, HSD17B6 has been linked to the regulation of pain modalities, including nociceptive pain and neuropathic pain.

HSD17B6 gene and opioids

The overuse of opioids for pain management can lead to various adverse effects, such as addiction, abuse, and dependence. The HSD17B6 gene has been suggested as a potential biomarker for monitoring the use of opioids. Several studies have shown that individuals with genetic variations in the HSD17B6 gene are more likely to develop opioid use disorder.

HSD17B6 gene and nonsteroidal anti-inflammatory drugs (NSAIDs)

NSAIDs are commonly used to treat pain and inflammation. However, the overuse of NSAIDs can lead to various adverse effects, such as stomach ulcers, bleeding, and eosinophilic asthma. The HSD17B6 gene has been shown to be involved in the metabolism of NSAIDs, including their biosynthesis and degradation. Therefore, the HSD17B6 gene could be a potential target for the development of safer and more effective NSAIDs.

HSD17B6 gene and other therapeutic approaches

Several therapeutic approaches have been proposed to target the HSD17B6 gene in order to treat chronic pain. One approach is to develop drugs that specifically target the HSD17B6 gene, such as small molecules or peptides that can modulate the activity of HSD17B6. Another approach is to use gene editing techniques to modify the HSD17B6 gene to produce less or

Protein Name: Hydroxysteroid 17-beta Dehydrogenase 6

Functions: NAD-dependent oxidoreductase with broad substrate specificity that shows both oxidative and reductive activity (in vitro). Has 17-beta-hydroxysteroid dehydrogenase activity towards various steroids (in vitro). Converts 5-alpha-androstan-3-alpha,17-beta-diol to androsterone and estradiol to estrone (in vitro). Has 3-alpha-hydroxysteroid dehydrogenase activity towards androsterone (in vitro). Has retinol dehydrogenase activity towards all-trans-retinol (in vitro). Can convert androsterone to epi-androsterone. Androsterone is first oxidized to 5-alpha-androstane-3,17-dione and then reduced to epi-andosterone. Can act on both C-19 and C-21 3-alpha-hydroxysteroids

The "HSD17B6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HSD17B6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets